Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease

Abstract

Asymmetric dimethylarginine (ADMA), an endogenous methylated form of the amino acid l-arginine, inhibits the activity of the enzyme endothelial nitric oxide synthase, with consequent reduced synthesis of nitric oxide. ADMA is metabolised to l-citrulline and dimethylamine by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). The modulation of DDAH activity and expression plays a pivotal role in regulating intracellular ADMA concentrations, with important effects on vascular homeostasis. For example, impairment in DDAH activity, resulting in elevated ADMA concentrations and reduced nitric oxide synthesis, can promote the onset and progression of atherosclerosis in experimental models. This review discusses the current role of ADMA and DDAH in vascular health and disease, the techniques used to assess DDAH activity and expression, and the results of recent studies on pharmacological and biological agents modulating DDAH activity and expression. Suggestions for future basic and clinical research directions are also discussed.

Keywords::

• asymmetric dimethylarginine
• atherosclerosis
• dimethylarginine dimethylaminohydrolase
• endothelium
• nitric oxide

Notes